Sanofi Wins EU Approval For Cenrifki As First Disability-Targeting Therapy For SPMS Without Relapses

Sanofi's Cenrifki (tolebrutinib) received European Commission approval as the first EU medicine specifically designed to slow disability progression in adults with secondary progressive multiple sclerosis. The approval is a meaningful regulatory milestone for Sanofi and expands treatment options in a high-need neurological disease area. The news is positive for the company, though the market impact is likely limited to the stock rather than the broader sector.

Analysis

Sanofi's Cenrifki (tolebrutinib) received European Commission approval as the first EU medicine specifically designed to slow disability progression in adults with secondary progressive multiple sclerosis. The approval is a meaningful regulatory milestone for Sanofi and expands treatment options in a high-need neurological disease area. The news is positive for the company, though the market impact is likely limited to the stock rather than the broader sector.